Compare FirstEnergy Corp. (FE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Incyte Corporation — how do they compare? FirstEnergy Corp. trades at $49.08 (market cap $28.13B), while Incyte Corporation trades at $116.04 (market cap $22.99B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays a 3.82% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FE | INCY | |
|---|---|---|
Market Cap | $28.13B | $22.99B |
Sector | Utilities | Health |
52-Week High | $51.91 | $118.52 |
52-Week Low | $40.30 | $67.38 |
Enterprise Value | $56.14B | $19.01B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy Corp. (FE) trades at $49.17, down 0.1% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue growth is steady at $15.09 billion for 2025. The company benefits from rising data center demand and a $36 billion investment plan, highlighted by recent news of grid upgrades and leadership appointments to drive operational performance.
Outlook is positive with a consensus price target of $52.00, offering ~6% upside. Key opportunities include infrastructure investments and data center growth, but risks involve high debt levels and regulatory pressures. Institutional sentiment is bullish with no sell ratings, though net cash flow remains negative, requiring careful monitoring of capital expenditures.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
